ARTICLE | Company News
Medarex, Novo Nordisk deal
January 16, 2001 8:00 AM UTC
MEDX will use its UltiMAb human antibody and T-12 preclinical development systems to develop antibodies against disease targets identified by NVO. NVO will develop and market resulting human antibody ...